These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 12645807)

  • 1. Effects of orthotopic liver transplantation on vasoactive systems and renal function in patients with advanced liver cirrhosis.
    Cassinello C; Moreno E; Gozalo A; Ortuño B; Cuenca B; Solís-Herruzo JA
    Dig Dis Sci; 2003 Jan; 48(1):179-86. PubMed ID: 12645807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems.
    Guevara M; Ginès P; Bandi JC; Gilabert R; Sort P; Jiménez W; Garcia-Pagan JC; Bosch J; Arroyo V; Rodés J
    Hepatology; 1998 Aug; 28(2):416-22. PubMed ID: 9696006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does hepatorenal syndrome affect the result of liver transplantation? Clinical observations.
    Park I; Moon E; Hwang JA; Yu S; Kim BW; Wang HJ; Shin GT; Kim H
    Transplant Proc; 2010 Sep; 42(7):2563-6. PubMed ID: 20832544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced external counterpulsation: a new technique to augment renal function in liver cirrhosis.
    Werner D; Trägner P; Wawer A; Porst H; Daniel WG; Gross P
    Nephrol Dial Transplant; 2005 May; 20(5):920-6. PubMed ID: 15788437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.
    Angeli P; Volpin R; Piovan D; Bortoluzzi A; Craighero R; Bottaro S; Finucci GF; Casiglia E; Sticca A; De Toni R; Pavan L; Gatta A
    Hepatology; 1998 Oct; 28(4):937-43. PubMed ID: 9755229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal and neurohormonal changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacyclin in cirrhotic patients with hepatorenal syndrome.
    Saló J; Ginès A; Quer JC; Fernández-Esparrach G; Guevara M; Ginès P; Bataller R; Planas R; Jiménez W; Arroyo V; Rodés J
    J Hepatol; 1996 Dec; 25(6):916-23. PubMed ID: 9007721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lack of renal improvement with nonselective endothelin antagonism with tezosentan in type 2 hepatorenal syndrome.
    Wong F; Moore K; Dingemanse J; Jalan R
    Hepatology; 2008 Jan; 47(1):160-8. PubMed ID: 17886336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of endothelin-1 in patients with the hepatorenal syndrome after successful liver transplantation.
    Bachmann-Brandt S; Bittner I; Neuhaus P; Frei U; Schindler R
    Transpl Int; 2000; 13(5):357-62. PubMed ID: 11052272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome.
    Wong F; Pantea L; Sniderman K
    Hepatology; 2004 Jul; 40(1):55-64. PubMed ID: 15239086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of patients with cirrhosis and hepatorenal syndrome type 1 treated with liver transplantation.
    Wong F; Leung W; Al Beshir M; Marquez M; Renner EL
    Liver Transpl; 2015 Mar; 21(3):300-7. PubMed ID: 25422261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular adsorbent recirculating system is ineffective in the management of type 1 hepatorenal syndrome in patients with cirrhosis with ascites who have failed vasoconstrictor treatment.
    Wong F; Raina N; Richardson R
    Gut; 2010 Mar; 59(3):381-6. PubMed ID: 19710033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatorenal syndrome.
    Gattoni A; Marotta F; Vangieri B; Pisani G; Cristiano F
    Clin Ter; 2004 Sep; 155(9):375-89. PubMed ID: 15700631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renal haemodynamics in patients with liver cirrhosis assessed by colour ultrasonography.
    Wang Y; Liu LP; Bai WY; Wen SB; Dan HJ; Luan YY; Zeng MX; Hu B
    J Int Med Res; 2011; 39(1):249-55. PubMed ID: 21672328
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of somatostatin on renal function in cirrhosis.
    Ginès A; Salmerón JM; Ginès P; Jiménez W; Saló J; Piera C; Clària J; Rivera F; Arroyo V; Rodés J
    Gastroenterology; 1992 Dec; 103(6):1868-74. PubMed ID: 1360435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The growing evidence that renal function should be improved in patients with cirrhosis and hepatorenal syndrome before liver transplantation.
    Moreau R
    J Hepatol; 2004 Jan; 40(1):159-61. PubMed ID: 14672628
    [No Abstract]   [Full Text] [Related]  

  • 17. Kidney injury in cirrhosis: pathophysiological and therapeutic aspects of hepatorenal syndromes.
    Møller S; Krag A; Bendtsen F
    Liver Int; 2014 Sep; 34(8):1153-63. PubMed ID: 24673771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatorenal syndrome. Studies of the effect of vascular volume and intraperitoneal pressure on renal and hepatic function.
    Cade R; Wagemaker H; Vogel S; Mars D; Hood-Lewis D; Privette M; Peterson J; Schlein E; Hawkins R; Raulerson D
    Am J Med; 1987 Mar; 82(3):427-38. PubMed ID: 3548346
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of pretransplant renal function on survival after liver transplantation.
    Gonwa TA; Klintmalm GB; Levy M; Jennings LS; Goldstein RM; Husberg BS
    Transplantation; 1995 Feb; 59(3):361-5. PubMed ID: 7871566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term terlipressin administration improves renal function in cirrhotic patients with type 1 hepatorenal syndrome: a pilot study.
    Mulkay JP; Louis H; Donckier V; Bourgeois N; Adler M; Deviere J; Le Moine O
    Acta Gastroenterol Belg; 2001; 64(1):15-9. PubMed ID: 11322061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.